TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05741216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTF Ocular Lubricant
Description: Ocular lubricant in 1 of 3 test formulations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTF Ocular Lubricant
Description: Ocular lubricant in 1 of 3 test formulations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTF Ocular Lubricant
Description: Ocular lubricant in 1 of 3 test formulations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ocular Lubricant
Description: Commercially available ocular lubricant
Study: NCT05381155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A single-session behavioral intervention composed of a brief evocation of the childbirth memory followed by a Tetris gameplay
Description: The intervention is composed of two tasks:~1. The childbirth narration task (8-10 min.): To trigger the malleability of the traumatic childbirth memory through memory reactivation, a psychologist will ask the participants to briefly narrate their childbirth and the moment associated with their most frequent or distressing CB-ITM. This intervention part will take place on the maternity ward to use this context as a reactivation cue.~2. The visuospatial task (3 min. practice + 20 min. gameplay): Participants will be instructed to engage in a Tetris gameplay for 20 minutes on a handheld gaming device (Nintendo 3DS), which is assumed to disrupt memory reconsolidation. This part of the intervention will take place in a neutral room.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A single-session behavioral intervention composed of a brief evocation of the childbirth memory followed by a Tetris gameplay
Description: The intervention is composed of two tasks:~1. The childbirth narration task (8-10 min.): To trigger the malleability of the traumatic childbirth memory through memory reactivation, a psychologist will ask the participants to briefly narrate their childbirth and the moment associated with their most frequent or distressing CB-ITM. This intervention part will take place on the maternity ward to use this context as a reactivation cue.~2. The visuospatial task (3 min. practice + 20 min. gameplay): Participants will be instructed to engage in a Tetris gameplay for 20 minutes on a handheld gaming device (Nintendo 3DS), which is assumed to disrupt memory reconsolidation. This part of the intervention will take place in a neutral room.
Study: NCT04713631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: Curcumin has been used in Indian cuisine and traditional medicine for centuries. It has low solubility in aqueous solution and yields low serum levels following oral administration. In the setting of inflammatory bowel disease where the required site of action is the bowel, systemic absorption may be less relevant. Curcumin and its reduced metabolites undergo conjugation in the liver. Curcumin has a half life of 6-7 hours. It has been found to be safe at oral doses of 2 gm and 3 gm a day in patients with ulcerative colitis, for up to 1 year. In a dose titration study conducted in children with inflammatory bowel disease 2 gm twice daily of curcumin was well tolerated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo A
Description: Artesunate looking placebo
Study: NCT06005233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartwatch
Description: Smartwatch with PPG- and 1-lead ECG derived analysis of cardiac arrhythmia. Analysis will be performed centrally at the Cardiology Core Lab at the Klinikum Rechts der Isar.
Study: NCT05901545

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given by IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indium In 111 Panitumumab
Description: Given by IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo SPECT/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo standard of care surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging agent
Description: Receive local injection of optical dye

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative Imaging
Description: Undergo Intraoperative Imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Near Infrared Imaging
Description: Undergo Near Infrared Imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocardiography
Description: Undergo Electrocardiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT06568562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL092
Description: XL092 will be supplied as a tablet that will be taken at home once a day. Participants should drink at least 8 ounces of water with each dose of XL092. Participants should not eat at least 2 hours before taking the dose and 1 hour after. Participants will be given enough XL092 to take at home for a full cycle.
Study: NCT06481709

Intervention type: DRUG
Group type: OTHER
Intervention: RLF-OD032
Description: 100 mg/mL oral suspension

Intervention type: DRUG
Group type: OTHER
Intervention: RLF-OD032
Description: 100 mg/mL oral suspension

Intervention type: DRUG
Group type: OTHER
Intervention: RLF-OD032
Description: 100 mg/mL oral suspension

Intervention type: DRUG
Group type: OTHER
Intervention: RLF-OD032
Description: 100 mg/mL oral suspension

Intervention type: DRUG
Group type: OTHER
Intervention: Kuvan
Description: 100 mg powder for oral solution

Intervention type: DRUG
Group type: OTHER
Intervention: Kuvan
Description: 100 mg powder for oral solution

Intervention type: DRUG
Group type: OTHER
Intervention: Kuvan
Description: 100 mg powder for oral solution

Intervention type: DRUG
Group type: OTHER
Intervention: Kuvan
Description: 100 mg powder for oral solution
Study: NCT06542198

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mannitol Infusion (blinded)
Description: 1 g of mannitol per kg body weight is infused in 30 minutes (≙ 5 ml/kg body weight), with an upper limit of 80 g, equivalent to a body weight of 80 kg or a volume of 400 ml. The solution used for infusion is 20% mannitol in water for injection and is administered at a rate of 0.17 ml/kg/min.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Placebo Infusion (blinded)
Description: 0.9% saline will be administered in the same amount as the mannitol dose infusion (= 5 ml/kg body weight), with a rate of 0.17 ml/kg/min in 30 minutes, with an upper limit of 400 ml (equivalent to a body weight of 80 kg).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mannitol Infusion (open label)
Description: 1 g of mannitol per kg body weight is infused in 30 minutes (≙ 5 ml/kg body weight), with an upper limit of 80 g, equivalent to a body weight of 80 kg or a volume of 400 ml. The solution used for infusion is 20% mannitol in water for injection and is administered at a rate of 0.17 ml/kg/min.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mannitol Infusion (open label)
Description: 1 g of mannitol per kg body weight is infused in 30 minutes (≙ 5 ml/kg body weight), with an upper limit of 80 g, equivalent to a body weight of 80 kg or a volume of 400 ml. The solution used for infusion is 20% mannitol in water for injection and is administered at a rate of 0.17 ml/kg/min.
Study: NCT06504615

Intervention type: DRUG
Intervention: nivolumab + chemotherapy
Description: As prescribed by the treating clinician, as per product label

Intervention type: DRUG
Intervention: nivolumab + chemotherapy
Description: As prescribed by the treating clinician, as per product label
Study: NCT04986176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-1119
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT06221566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: Muscle energy technique (MET) for upper trapezius and levetor scapulae muscle of neck with 7 to 10 second hold, 3 to 5 repetitions.~Transcutaneous electrical nerve stimulation (TENS) with Cold pack.~Home exercise program (HEP) will receive by both the groups which will be not supervised by the principal investigator or any other investigator.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Exercises
Description: Stretching exercises program for upper trapezius and levetor scapulae muscle of neck with 10 second hold, 15 repetitions.~Transcutaneous electrical nerve stimulation (TENS) with Cold pack.~Home exercise program (HEP) will receive by both the groups which will be not supervised by the principal investigator or any other investigator.
Study: NCT05536362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCI Propofol Injection
Description: To decrease postoperative pain after cancer colon surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCI Propofol Injection
Description: To decrease postoperative pain after cancer colon surgery
Study: NCT06073821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonrotoclax
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: Administered intravenously
Study: NCT04718220

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Antibody testing for SARS-CoV-2 IgG
Description: Women enrolled into the unexposed (SARS-CoV-2 negative) cohort will undergo testing for SARS-CoV-2 IgG antibodies at enrollment, every trimester of pregnancy, and during delivery hospitalization.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Testing for SARS-CoV-2 RNA
Description: Women in the exposed (SARS-CoV-2 positive) cohort will undergo testing of placental tissue, umbilical cord blood, amniotic tissue, and neonates for SARS-CoV-2 RNA, as available.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Testing for SARS-CoV-2 IgM/IgG
Description: Women in the exposed (SARS-CoV-2 positive) cohort will undergo testing of umbilical cord blood for SARS-CoV-2 IgG and IgM antibodies, as available.
Study: NCT06580171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking and Remembering Test
Description: Only Walking and Remembering Test will be applied to the group.
Study: NCT05840432

Intervention type: DEVICE
Intervention: Postoperative hypotension prediction index
Description: Performance of the hypotension prediction index (HPI) in predicting hypotension episodes in the first 12 h of cardiac surgery postoperative
Study: NCT06298916

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 64Cu-LNTH-1363S
Description: 64Cu-LNTH-1363S, is a highly selective, high affinity FAP inhibitor (FAPi) that is radiolabeled with Copper-64 (64Cu) for PET/CT Imaging,

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 64Cu-LNTH-1363S
Description: 64Cu-LNTH-1363S, is a highly selective, high affinity FAP inhibitor (FAPi) that is radiolabeled with Copper-64 (64Cu) for PET/CT Imaging,
Study: NCT05661734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablets for oral administration.
Study: NCT06102057

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard Radiotherapy
Description: standard FDG-PET-based radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: concurrent standard of care chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: concurrent standard of care chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunotherapy
Description: standard of care consolidation therapy with durvalumab (fixed dose of 1500 mg q4w) for up to 12 months or until progression of disease, unacceptable toxicity, patient´s wish, or investigator´s decision, whichever comes first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: standard of care consolidation therapy with durvalumab (fixed dose of 1500 mg q4w) for up to 12 months or until progression of disease, unacceptable toxicity, patient´s wish, or investigator´s decision, whichever comes first.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Experimental Radiotherapy
Description: FDG-PET-based small volume accelerated radiotherapy
Study: NCT06097728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volrustomig
Description: MEDI5752: Administered as IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Alimta: Administered as IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Alimta: Administered as IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Paraplatin: Administered as IV infusion
Study: NCT04713631

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo A
Description: Artesunate looking placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo C
Description: Curcumin looking placebo
Study: NCT06097728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Paraplatin: Administered as IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Platinol: Administered as IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Opdivo: Administered as IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Yervoy: Administered as IV infusion
Study: NCT05534009

Intervention type: OTHER
Intervention: Follow up of the first known immunization event
Description: The baseline for enrolment into the study is defined by the occurrence of the first known immunization event, either natural infection or vaccination. The follow-up is planned to last 24 months with respect to this baseline. In subjects with natural infection, the viral variant must be determined for each prospective case by analysis of a nasopharyngeal swab obtained as soon as possible at diagnosis. For historical cases where the variant was not determined and a contemporary nasopharyngeal swab has not been stored, the viral variant may be inferred when a specific variant was dominating the geographic area according to official records available at local health agencies. However, the variant assignment will be labelled as putative, rather than proved.~HCWs can be enrolled in the category of:~(i) vaccination not followed by any later infection, (ii) infection followed by vaccination and (iii) vaccination followed by infection.
Study: NCT06576726

Intervention type: OTHER
Intervention: This study involves no intervention.
Description: This study involves no intervention.

Intervention type: OTHER
Intervention: This study involves no intervention.
Description: This study involves no intervention.
Study: NCT06133387

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection using the ELS System
Description: All subjects will undergo endoscopic submucosal dissection, with or without closure at the discretion of the Investigator, of benign lesions in the rectum and sigmoid colon.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection using the ELS System
Description: All subjects will undergo endoscopic submucosal dissection, with or without closure at the discretion of the Investigator, of benign lesions in the rectum and sigmoid colon.
Study: NCT04526795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcrisantaspase
Description: Given IV
Study: NCT05175755

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients
Description: The procedure involves taking a total of 12 ml of blood.
Study: NCT04713631

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo C
Description: Curcumin looking placebo
Study: NCT05618795

Intervention type: OTHER
Group type: OTHER
Intervention: minimal gap arthoplasty v/s aggressive gap arthoplasty
Description: Comparative evaluation of aggressive gap arthroplasty with minimal gap arthroplasty in the management of TMJ ankylosis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: minimal gap arthoplasty v/s aggressive gap arthoplasty
Description: Comparative evaluation of aggressive gap arthroplasty with minimal gap arthroplasty in the management of TMJ ankylosis
Study: NCT04847869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ellex Integre NIR laser
Description: The Ellex Integre NIR (near Infrared Light) Laser dose of 200 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
Study: NCT05279170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAVEPPIC: MAsk VEntilation with Paratracheal Pressure In Children
Description: Pressure will be applied with two fingers in the area located between the trachea and the sternal head of the sternocleidomastoid muscle on the left side to compress the cervical esophagus.~The force applied (after measuring the equivalent force applied on a precision scale) will be about 10 - 15 N. This force will be adapted according to the child's body weight : 10 N below 20 kgs and 15 N between 20 kgs and 40 kgs
Study: NCT06285877

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy sessions
Description: Conventional sessions are neuropsychology, speech therapy, physiotherapy and occupational therapy treatments. They are based on cognitive stimulation, manipulative dexterity, therapeutic exercise.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional therapy sessions plus Nintendo Switch
Description: Conventional sessions are neuropsychology, speech therapy, physiotherapy and occupational therapy treatments. They are based on cognitive stimulation, manipulative dexterity, therapeutic exercise plus one hour a week of Nintendo Switch.
Study: NCT05646667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interscalene with Erector spinae plane block group
Description: patients will receive interscalene brachial plexus block using 10 ml of bupivacaine 0.5% and US guided Erector spinae plane block at T2 using 10 ml of bupivacaine 0.5%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interscalene group
Description: patients will receive interscalene brachial plexus block using 15 ml of bupivacaine 0.5%.
Study: NCT06378554

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cereset Research
Description: The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM). The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
Study: NCT05845320

Intervention type: OTHER
Intervention: ICIQ-UI SF questionnaire
Description: validated arabic short form of ICIQ on urinary incontinence

Intervention type: OTHER
Intervention: ICIQ-UI SF questionnaire
Description: validated arabic short form of ICIQ on urinary incontinence
Study: NCT05178160

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEEP Standard Protocol
Description: All the patients treated with CPAP receive a PEEP standard of 10 cmH2O with a fixed FiO2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP Standard Protocol
Description: All the patients treated with CPAP receive a PEEP standard of 10 cmH2O with a fixed FiO2
Study: NCT06217367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg Diphenhydramine
Description: Participants ingest 50mg of diphenhydramine orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg Loratadine
Description: Participants ingest 10 mg of loratadine orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Desloratadine
Description: Participants ingest 5 mg of desloratadine orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Sugar Pill)
Description: Participants ingest placebo pill orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.
Study: NCT04962425

Intervention type: DRUG
Intervention: Trastuzumab
Description: Trastuzumab \[Herceptin\] is a recombinant DNA-humanized monoclonal antibody that selectively targets the HER-2 receptor on the surface of tumor cells.

Intervention type: DRUG
Intervention: Trastuzumab
Description: Trastuzumab \[Herceptin\] is a recombinant DNA-humanized monoclonal antibody that selectively targets the HER-2 receptor on the surface of tumor cells.
Study: NCT06332885

Intervention type: DEVICE
Intervention: Zephyr Endobronchial Valve
Description: Zephyr Valve provides an alternative technique to achieve bronchoscopic lung volume reduction (BLVR) using a minimally invasive approach. Zephyr Valve is a tiny unidirectional valve. During BLVR, multiple valves are placed to occlude a hyperinflated lobe of the lungs, allowing air to escape while blocking airflow into the treated lobe. This is intended to result in a reduction in lung volume and hyperinflation in the targeted area. Consequently, the remaining lobes can expand more fully, the overall lung works more efficiently, with resultant improvement in overall lung function in patients with hyperinflation associated with severe emphysema.